SEC Form SC 13G filed by Merus N.V.

11/12/24 10:32:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRUS alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 MERUS NV COMMON STOCK Cusip #N5749R100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #N5749R100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,814,224 Item 6: 0 Item 7: 6,814,226 Item 8: 0 Item 9: 6,814,226 Item 11: 9.989% Item 12: HC Cusip #N5749R100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,814,226 Item 8: 0 Item 9: 6,814,226 Item 11: 9.989% Item 12: IN Item 1(a). Name of Issuer: MERUS NV Item 1(b). Address of Issuer's Principal Executive Offices: YALELAAN 62 UTRECHT, 3584 CM NETHERLANDS Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: N5749R100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 6,814,226 (b) Percent of Class: 9.989% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,814,226 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of MERUS NV. No one other person's interest in the COMMON STOCK of MERUS NV is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of MERUS NV at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $MRUS alert in real time by email

Recent Analyst Ratings for

$MRUS

Date	Price Target	Rating	Analyst
9/17/2025	$112.00	Overweight	Barclays
8/25/2025	$90.00	Buy	Alliance Global Partners
2/13/2025	$84.00	Overweight	Piper Sandler
2/7/2025	$91.00	Overweight	Wells Fargo
11/21/2024	$73.00	Buy	Goldman
10/24/2024	$72.00	Buy	UBS
3/28/2024	$69.00	Buy	Truist
3/4/2024	$42.00 → $65.00	Buy	Needham

More analyst ratings

SEC Form SC 13G filed by Merus N.V.

11/12/24 10:32:13 AM ET

$MRUS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRUS alert in real time by email

Recent Analyst Ratings for

$MRUS

Date	Price Target	Rating	Analyst
9/17/2025	$112.00	Overweight	Barclays
8/25/2025	$90.00	Buy	Alliance Global Partners
2/13/2025	$84.00	Overweight	Piper Sandler
2/7/2025	$91.00	Overweight	Wells Fargo
11/21/2024	$73.00	Buy	Goldman
10/24/2024	$72.00	Buy	UBS
3/28/2024	$69.00	Buy	Truist
3/4/2024	$42.00 → $65.00	Buy	Needham

More analyst ratings

SEC Form SC 13G filed by Merus N.V.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MRUS

SEC Form SC 13G filed by Merus N.V.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MRUS

$MRUS SEC Filings

SEC Form 15-12G filed by Merus N.V.

Amendment: SEC Form SCHEDULE 13D/A filed by Merus N.V.

Amendment: SEC Form 25-NSE/A filed by Merus N.V.

$MRUS Insider Trading

Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)

$MRUS Insider Purchases

Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)

$MRUS FDA approvals

FDA Approval for BIZENGRI issued to MERUS N.V.

FDA Approval for BIZENGRI issued to MERUS N.V.

December 6, 2024 - FDA Roundup: December 6, 2024

$MRUS Press Releases

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

$MRUS Analyst Ratings

Barclays initiated coverage on Merus with a new price target

Alliance Global Partners initiated coverage on Merus with a new price target

Piper Sandler initiated coverage on Merus with a new price target

$MRUS Financials

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

$MRUS Leadership Updates

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

$MRUS Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Merus N.V.

Amendment: SEC Form SC 13G/A filed by Merus N.V.

Amendment: SEC Form SC 13G/A filed by Merus N.V.

Recent Analyst Ratings for
$MRUS

Recent Analyst Ratings for
$MRUS

$MRUS
SEC Filings

$MRUS
Insider Trading

$MRUS
Insider Purchases

$MRUS
FDA approvals

$MRUS
Press Releases

$MRUS
Analyst Ratings

$MRUS
Financials

$MRUS
Leadership Updates

$MRUS
Large Ownership Changes